Cargando…
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer
PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554783/ https://www.ncbi.nlm.nih.gov/pubmed/28816160 http://dx.doi.org/10.1016/j.ijrobp.2017.04.026 |
_version_ | 1783256844610830336 |
---|---|
author | Vivekanandan, S. Landau, D.B. Counsell, N. Warren, D.R. Khwanda, A. Rosen, S.D. Parsons, E. Ngai, Y. Farrelly, L. Hughes, L. Hawkins, M.A. Fenwick, J.D. |
author_facet | Vivekanandan, S. Landau, D.B. Counsell, N. Warren, D.R. Khwanda, A. Rosen, S.D. Parsons, E. Ngai, Y. Farrelly, L. Hughes, L. Hawkins, M.A. Fenwick, J.D. |
author_sort | Vivekanandan, S. |
collection | PubMed |
description | PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy. METHODS AND MATERIALS: Dosimetric and survival data were analyzed for 78 patients. The whole heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles (LV/RV-Wall) were outlined on radiation therapy planning scans, and differential dose-volume histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the average dDVH and the 10 highest-ranked structure-specific principal components (PCs). ECGs at baseline and 6 months after radiation therapy were analyzed for 53 patients, dichotomizing patients according to presence or absence of “any ECG change” (conduction or ischemic/pericarditis-like change). All-cause death rate (DR) was analyzed from the start of treatment using Cox regression. RESULTS: 38% of patients had ECG changes at 6 months. On univariable analysis, higher scores for LA-Wall-PC6, Heart-PC6, “any ECG change,” and larger planning target volume (PTV) were significantly associated with higher DR (P=.003, .009, .029, and .037, respectively). Heart-PC6 and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63 to 69 Gy. Cardiac doses ≥63 Gy were concentrated in the LA-Wall, and consequently Heart-PC6 was highly correlated with LA-Wall-PC6. “Any ECG change,” LA-Wall-PC6 scores, and PTV size were retained in the multivariable model. CONCLUSIONS: We found associations between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63 to 69 Gy in this small cohort of patients. |
format | Online Article Text |
id | pubmed-5554783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier Science Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-55547832017-09-01 The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer Vivekanandan, S. Landau, D.B. Counsell, N. Warren, D.R. Khwanda, A. Rosen, S.D. Parsons, E. Ngai, Y. Farrelly, L. Hughes, L. Hawkins, M.A. Fenwick, J.D. Int J Radiat Oncol Biol Phys Clinical Investigation PURPOSE: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy. METHODS AND MATERIALS: Dosimetric and survival data were analyzed for 78 patients. The whole heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles (LV/RV-Wall) were outlined on radiation therapy planning scans, and differential dose-volume histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the average dDVH and the 10 highest-ranked structure-specific principal components (PCs). ECGs at baseline and 6 months after radiation therapy were analyzed for 53 patients, dichotomizing patients according to presence or absence of “any ECG change” (conduction or ischemic/pericarditis-like change). All-cause death rate (DR) was analyzed from the start of treatment using Cox regression. RESULTS: 38% of patients had ECG changes at 6 months. On univariable analysis, higher scores for LA-Wall-PC6, Heart-PC6, “any ECG change,” and larger planning target volume (PTV) were significantly associated with higher DR (P=.003, .009, .029, and .037, respectively). Heart-PC6 and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63 to 69 Gy. Cardiac doses ≥63 Gy were concentrated in the LA-Wall, and consequently Heart-PC6 was highly correlated with LA-Wall-PC6. “Any ECG change,” LA-Wall-PC6 scores, and PTV size were retained in the multivariable model. CONCLUSIONS: We found associations between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63 to 69 Gy in this small cohort of patients. Elsevier Science Inc 2017-09-01 /pmc/articles/PMC5554783/ /pubmed/28816160 http://dx.doi.org/10.1016/j.ijrobp.2017.04.026 Text en Crown Copyright © Published by Elsevier Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Clinical Investigation Vivekanandan, S. Landau, D.B. Counsell, N. Warren, D.R. Khwanda, A. Rosen, S.D. Parsons, E. Ngai, Y. Farrelly, L. Hughes, L. Hawkins, M.A. Fenwick, J.D. The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title_full | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title_fullStr | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title_full_unstemmed | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title_short | The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer |
title_sort | impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554783/ https://www.ncbi.nlm.nih.gov/pubmed/28816160 http://dx.doi.org/10.1016/j.ijrobp.2017.04.026 |
work_keys_str_mv | AT vivekanandans theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT landaudb theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT counselln theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT warrendr theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT khwandaa theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT rosensd theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT parsonse theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT ngaiy theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT farrellyl theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT hughesl theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT hawkinsma theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT fenwickjd theimpactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT vivekanandans impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT landaudb impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT counselln impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT warrendr impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT khwandaa impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT rosensd impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT parsonse impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT ngaiy impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT farrellyl impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT hughesl impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT hawkinsma impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer AT fenwickjd impactofcardiacradiationdosimetryonsurvivalafterradiationtherapyfornonsmallcelllungcancer |